Jefferies (NYSE:JEF) analyst David Steinberg reiterated a Buy rating on Bausch Health Companies (NYSE:BHC) Inc on Wednesday, setting a price target of $37, which is approximately 16.02% above the present share price of $31.89.
Steinberg expects Bausch Health Companies Inc to post earnings per share (EPS) of -$1.71 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Moderate Buy rating of shares in Bausch Health Companies, with an average price target of $37.5.
The analysts price targets range from a high of $55 to a low of $27.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $2.03 billion and a net profit of $378 million. The company's market cap is $11.43 billion.
According to TipRanks.com, Jefferies analyst David Steinberg is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 9.8% and a 52.65% success rate.
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.